Fibromyalgia Developed after Administration of Gonadotrophin- Releasing Hormone Analogue

Éric Toussirot, E Toussirot, Daniel Wendling, D Wendling
Clinical rheumatology · 2001 · vol. 20(2) , pp. 150–152 · doi:10.1007/pl00011195 · PMID:11346231 · W2082841333
article OA: closed CC0 ⤵ 2 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-12 ⓘ

This case report describes a woman who developed fibromyalgia symptoms, including widespread pain and sleep difficulties, after treatment with a gonadotrophin-releasing hormone analogue for endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-12 · read from full text ⓘ

This paper reports a clinical case of a woman with endometriosis who was treated with a gonadotrophin-releasing hormone analogue and subsequently developed typical fibromyalgia features, including widespread musculoskeletal pain, sleep difficulties, neuropsychological complaints, and tender points on examination. The authors discuss that the treatment probably induced disturbances in the neuroendocrine system and altered neurotransmitter secretion as a potential causal mechanism. The main limitation is that this is a single case report, so no definitive causal inference can be made. This paper is centrally about endometriosis — it describes fibromyalgia developing after administration of a gonadotrophin-releasing hormone analogue given specifically for endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 988 characters · extracted from oa-doi-fallback · click to expand
Abstract: We report the case of a woman treated with a gonadotrophin-releasing hormone analogue for endometriosis who developed typical clinical features of fibromyalgia, with widespread musculoskeletal pain, sleep difficulties, neuropsychological complaints and tender points on clininal examination. The gonadotrophin-releasing hormone analogue treatment probably induced disturbances in the neuroendocrine system and the secretion of neurotransmitters, and may be suspected to be the cause of this case of fibromyalgia. Similar content being viewed by others Author information Authors and Affiliations Additional information Received: 3 May 2000 / Accepted: 25 October 2000 Rights and permissions About this article Cite this article Toussirot, E., Wendling, D. Fibromyalgia Developed after Administration of Gonadotrophin- Releasing Hormone Analogue. Clin Rheumatol 20, 150–152 (2001). https://doi.org/10.1007/PL00011195 Published: Issue date: DOI: https://doi.org/10.1007/PL00011195

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Antineoplastic Agents, Hormonal Endometriosis Fibromyalgia Leuprolide Adult Antineoplastic Agents, Hormonal Endometriosis Endometriosis Female Fibromyalgia Fibromyalgia Humans Leuprolide

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

References (6)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:13:24.901228+00:00
unpaywall
last seen: 2026-06-13T17:26:54.343160+00:00
License: CC0 · commercial use OK